TP53 and prolymphocytic leukemia: al. demonstrated that in 2 cases of B-PLL with TP53 dysfunctions, when the patients were treated with Ibrutinib as second-line therapy, the tumor burden decreased.[17] Moore et al[18] reported that in 6 patients receiving a treatment regimen containing Ibrutinib as initial therapy for B-PLL, the response rate was 83.3%, the median progression-free survival was 34.7 months (range 2.6–50.5 months), but the median overall survival was not available.